IP Library › Granted Patent US 11,261,240
Granted Patent B2
US 11,261,240 · App. 17/124,747 · Granted Mar 1, 2022

Immuno-based botulinum toxin serotype A activity assays

Inventors: Ester Fernandez-Salas (Ann Arbor, MI); Joanne Wang (Irvine, CA); Patton E. Garay (Long Beach, CA); Lina Wong (Irvine, CA); D. Diane Hodges (Tustin, CA); Kei Roger Aoki (Coto De Caza, CA)
Assignee: Allergan, Inc.
C07K16/1282C12Q1/37G01N33/56911C07K2317/34C07K2317/77G01N2333/33G01N2333/705G01N2333/952
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,261,240
App. No.
17/124,747
Granted
Mar 1, 2022
Kind
B2
Abstract

The present specification discloses SNAP-25 compositions, methods of making α-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P 1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, α-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P 1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, methods of detecting BoNT/A activity, and methods of detecting neutralizing α-BoNT/A antibodies.

Claims (16)

1. A differentiated mammalian neuroblastoma cell susceptible to intoxication by about 10 pM or less of a botulinum neurotoxin serotype A (BoNT/A), wherein the susceptibility to intoxication is the lower limit of quantitation of cleaved BoNT/A substrate as determined by Western blot.

2. The differentiated mammalian neuroblastoma cell of claim 1 , wherein the cell is a differentiated SiMa cell or a differentiated Neuro-2a cell.

3. The differentiated mammalian neuroblastoma cell of claim 1 , wherein the cell is susceptible to intoxication by about 1 pM or less of BoNT/A.

4. The differentiated mammalian neuroblastoma cell of claim 1 , wherein the cell comprises a non-naturally occurring Synaptosomal-Associated Protein of 25 kDa (SNAP-25).

5. The differentiated mammalian neuroblastoma cell of claim 4 , wherein the non-naturally occurring SNAP-25 comprises a fluorophore.

6. The differentiated mammalian neuroblastoma cell of claim 1 , wherein the susceptibility to intoxication is measured by disappearance of an intact BoNT/A substrate.

7. The differentiated mammalian neuroblastoma cell of claim 6 , wherein the intact BoNT/A substrate is a non-naturally occurring SNAP-25.

8. The differentiated mammalian neuroblastoma cell of claim 6 , wherein the susceptibility to intoxication is measured following incubation of the cell in serum-free media for between about 24 and about 72 hours.

9. The differentiated mammalian neuroblastoma cell of claim 8 , wherein BoNT/A is present in the serum-free media for between about 24 to about 72 hours.

10. The differentiated mammalian neuroblastoma cell of claim 1 , wherein the Western blot is performed using S9684 α-SNAP-25 rabbit polyclonal antiserum as primary detection antibody.

11. A Neuro-2a cell susceptible to intoxication by about 10 pM or less of a BoNT/A, wherein the susceptibility to intoxication is the lower limit of quantitation of cleaved BoNT/A substrate as determined by Western blot following incubation of the cell in serum-free media for between about 24 hours and about 72 hours.

12. The Neuro-2a cell of claim 11 , wherein BoNT/A is present in the serum-free media for between about 24 hours and about 72 hours.

13. The Neuro-2a cell of claim 11 , wherein the cell comprises a non-naturally occurring SNAP-25.

14. The Neuro-2a cell of claim 13 , wherein the non-naturally occurring SNAP-25 comprises a fluorophore.

15. The Neuro-2a cell of claim 11 , wherein the Western blot is performed using S9684 α-SNAP-25 rabbit polyclonal antiserum as primary detection antibody.

16. The Neuro-2a cell of claim 11 , wherein the cell is susceptible to intoxication by about 1 pM or less of BoNT/A.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 10, 2022
From: FERNANDEZ-SALAS, ESTER; WANG, JOANNE; GARAY, PATTON E.; WONG, LINA; HODGES, D. DIANNE; AOKI, KEI ROGER
To: ALLERGAN, INC.
Reel/Frame 058605/0232 →
Continuity (7)
Continuation 16920031 · Jul 2, 2020
Continuation 15400618 · Jan 6, 2017
Division 13649923 · Oct 11, 2012
Continuation 13475553 · May 18, 2012
Division 12403531 · Mar 13, 2009
Provisional Application 61036723 · Mar 14, 2008
Related Publication 20210171614A1 · Jun 10, 2021
Cited By (1)
US 12,502,420